NRSN•benzinga•
D. Boral Capital Initiates Coverage On NeuroSense Therapeutics with Buy Rating, Announces Price Target of $14
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 12, 2025 by benzinga